Why Covid vaccines did not win science Nobel this year

Despite high hopes that one of Nobel committees would recognise vaccination research that has saved countless lives, this year's science Nobels instead went to fundamental advances

Nobel, Nobel Prize
A national library employee shows a gold Nobel Prize medal in Bogota, Colombia | AP/PTI
IANS New York
2 min read Last Updated : Oct 10 2021 | 4:06 PM IST

Despite high hopes that one of the Nobel committees would recognise vaccination research that has saved countless lives by being delivered to billions of people, this year's science Nobels instead went to fundamental advances that had been tipped to win for years.

The timing didn't work in favour of a Covid-19 Nobel this year. Nominations for this year's prize had to be submitted by February 1.

This was more than two months after the first mRNA vaccines, and some others, proved their mettle in clinical trials, but before their impact on the pandemic was fully clear, said Goran Hansson, secretary-general of the Royal Swedish Academy of Sciences in Stockholm, which selects the prize winners.

"Follow-up is really still happening now," Hansson added.

According to Nature.com, some scientists expressed surprise and disappointment at the omission of Covid-19 vaccines, particularly those developed using messenger RNA technology, which has launched a new class of vaccines.

But Nobel prize insiders and watchers say that timing, technical details and politics meant that a nod this year was a long shot.

However, the impact of Covid-19 vaccines -- and the underlying advances -- indicate that it shouldn't be long before researchers behind the work get a call from Stockholm.

"The development of mRNA vaccines is a wonderful success story that has had enormous positive consequences for humankind. And we are all very grateful to the scientists," Hansson said.

"This is a kind of discovery that will receive nominations. But we need to take time," Hansson added.

--IANS

vc/dpb

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus Vaccine

First Published: Oct 10 2021 | 4:06 PM IST

Next Story